Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill…

Meta-analysisJournal of the American College of Cardiology· Jul 2026

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Tobias Tritschler, Valentin Fuster, Patrick R Lawler … Anticoagulation in COVID-19 Investigators

Venous ThromboembolismMeta-analysisClinical practiceQ1IF 9.1

Full-dose blood thinners lowered odds of organ support or death in hospitalized COVID-19

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Tobias Tritschler … Anticoagulation in COVID-19 Investigators

Journal of the American College of Cardiology · Jul 2026

Background

Public health emergencies require rapid generation, synthesis, and translation of clinical evidence into practice guidelines; yet, systematic synthesis of the challenges and lessons from these processes remains limited.

Purpose

The purpose of this study was to examine how evidence on anticoagulation in COVID-19 was generated and translated into clinical guidance, using randomized controlled trials (randomized controlled trials) as a case study, and to contextualize these processes with an individual participant data meta-analysis (individual participant data meta-analysis).

Methods

Trial characteristics, evidence accumulation, and associated guideline recommendations were summarized over time.

n = 6,362 patients

Results

lower chance of needing organ support or dying with full-dose blood thinners

OR by subgroup · 95% CI

More results

Evidence evolved from an early coordinated platform randomized controlled trials (preprint May 2021) to subsequent randomized controlled trials published between June 2021 and July 2023.

More results

In exploratory counterfactual sequential individual participant data meta-analysis, the pooled treatment effect on organ support or death became statistically significant in May 2021, approximately 13 months after first patient enrollment (adjusted OR: 0.73; 95% CI: 0.58-0.91; 6 randomized controlled trials, n = 3,944).

“

Conclusion · 1 of 2

The COVID-19 anticoagulation experience highlights how delays in coordination, data sharing, and synthesis can slow the translation of evidence into practice.

Conclusion · 2 of 2

Therapeutic-dose anticoagulation was associated with reduced odds of organ support or death and, in this context, serves as a case study of how evidence emerges and is acted upon under conditions of uncertainty.

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients.

Related papers